TRANSTHERA-B (02617) completed the placement of a total of 2.1 million shares, raising approximately HK$190 million.

TRANSTHERA-B (02617) announced that all conditions set forth in the placement agreement have been met, and the completion was implemented on January 20, 2026. The placement agent successfully placed a total of 2.1 million shares at a placement price of HK$92.85 per share to no less than six subscribers. The 2.1 million shares represent approximately 0.70% of the existing issued H shares and approximately 0.53% of the existing issued share capital of the Company immediately before completion. After the issuance and placement of the shares, it represents approximately 0.69% of the expanded issued H shares and approximately 0.53% of the issued share capital of the Company. The total amount raised from the placement is approximately HK$195 million, with a net amount (after deduction of placement commission and other related costs and expenses) of approximately HK$190 million. Based on this, the net issue price is approximately HK$90.54 per share. The Company intends to allocate the net proceeds from the placement as follows (after deduction of issuance expenses): approximately 60%, or approximately HK$114 million, for funding the clinical trial of our core product Tinengotinib in monotherapy for cholangiocarcinoma (CCA) in China and research and development for other indications of our core product; approximately 30%, or approximately HK$57.04 million, for research and development of other products, including TT-00973, TT-01488, and other molecules; and approximately 10%, or approximately HK$19.01 million, for working capital and general corporate purposes.